Navigating the neutropenic abyss with granulocyte transfusions: Retrospective single‐center analysis of effectiveness and safety in India

Abstract

AbstractBackgroundHemato‐oncologic patients receiving intensive chemotherapy may develop severe neutropenia and serious bacterial and/or fungal infections. Granulocyte transfusions (GTs) may be beneficial as a bridging therapy in hemato‐oncologic patients with febrile neutropenia.AimTo evaluate the clinical effectiveness of GTs in hemato‐oncologic patients with febrile neutropenia.Materials and MethodsThis retrospective study evaluated the effectiveness of 150 GTs in 88 hemato‐oncologic patients. Donors were mobilized with granulocyte colony‐stimulating factors and dexamethasone. Patients' hematological parameters (pre‐ and post‐GT) and safety and effectiveness of GTs were analyzed.ResultsThe safety and effectiveness of GTs were assessed in the patients with various underlying conditions, including 78% with acute myeloid leukemia. In total, 150 GTs were administered, mostly during the chemotherapy induction phase. The GTs were well‐tolerated by the patients, and a significant increment in white blood cell count and absolute neutrophil count (ANC) was noticed in 95% of patients after the transfusion. The granulocyte dose was positively correlated with ANC after the transfusion. The average time to neutrophil recovery from the last day of GT was 6.7 days, and the 30‐day survival rate was 77%. The donors were all men, and a significant increase in WBC count was observed post‐mobilization. The median granulocyte yield was 2.28 × 1010/unit. All granulocyte products were crossmatched and irradiated before the transfusion.ConclusionGTs can be a useful adjunctive treatment for febrile neutropenia in hemato‐oncologic patients with multidrug‐resistant sepsis. However, additional studies are required for confirming their effectiveness and establishing guidelines for their use.